The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC).
Sandrine J. Faivre
Honoraria - Lilly
Research Funding - Lilly
Armando Santoro
No relevant relationships to disclose
Robin Kate Kelley
Research Funding - Lilly
Philippe Merle
No relevant relationships to disclose
Ed Gane
No relevant relationships to disclose
Jean-Yves Douillard
Consultant or Advisory Role - Bayer; Lilly
Honoraria - Bayer
Dirk Waldschmidt
No relevant relationships to disclose
Mary Frances Mulcahy
No relevant relationships to disclose
Charlotte Costentin
No relevant relationships to disclose
Beatriz Minguez
No relevant relationships to disclose
Pasqua Papappicco
No relevant relationships to disclose
Ivelina Gueorguieva
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Ann Cleverly
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Durisala Desaiah
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Michael M. Lahn
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Sophie Ameryckx
Employment or Leadership Position - Lilly
Karim A. Benhadji
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Eric Raymond
Consultant or Advisory Role - Lilly
Research Funding - Lilly
Gianluigi Giannelli
Research Funding - Lilly